In July 2003, the Office of Population Affairs (OPA) at the U.S. Department of Health and Human Services formally requested applications for $49 million for family planning service delivery under the Title X program for FY 2004. The announcement contains a number of new program priorities that will affect the delivery of subsidized family planning services for millions of low-income women and teens in the years to come.
You have just examined a young woman who reports she has had recent multiple sexual partners and says she has used irregular protection against sexually transmitted disease (STD). You order lab tests, including a screen for chlamydia. When positive results return the next day, will she come back for treatment?
A new analysis of worldwide evidence on the possible relation between breast cancer and previous spontaneous and induced abortions reaffirms earlier findings that pregnancies that end in abortion do not increase a womans risk of developing breast cancer.
The new World Health Organization (WHO) Medical Eligibility Criteria (MEC) for Contraceptive Use are being released this spring. The changes made will dramatically affect the provision of contraceptives throughout the world. These are the 10 recommendations that have changed the most.
New guidelines for the treatment of bacterial rhinosinusitis were published in the January supplement of Otolaryngology-Head and Neck Surgery by the Sinus and Allergy Health Partnership.
Your next patient is a 17-year-old female who is interested in contraception. While she says she knows about the contraceptive patch and the vaginal ring, when you ask her about their effectiveness in preventing sexually transmitted diseases (STDs), she gives you a puzzled look.
Two potential candidates in the microbicide research pipeline are set to be examined in clinical trials this fall, with research to focus on the safety and acceptability in healthy women and women infected with HIV.
The emergency contraceptive (EC) Plan B may be available over the counter (OTC) to women ages 16 and older if the Food and Drug Administration (FDA) approves Pomona, NY-based Barr Pharmaceuticals revised request for OTC status.
